Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 12:11:1464526.
doi: 10.3389/fnut.2024.1464526. eCollection 2024.

Effects of fish oil supplementation on bone turnover markers in depression: a pilot study

Feifei Wang #  1   2 , Hui Yuan #  3 , Kun Jin  4 , Hui Tang  4 , Jimin Guo  5 , Chuan-Yue Wang  1   2 , Jindong Chen  4 , Fang Dong  1   2 , Lu Wang  1   2   4
Affiliations

Effects of fish oil supplementation on bone turnover markers in depression: a pilot study

Feifei Wang et al. Front Nutr. .

Abstract

Background and objective: There is a close correlation between bone loss, depression, and antidepressants. N-3 PUFA supplementation has been considered an effective add-on therapeutic approach in ameliorating bone loss and relieving depression. However, the adjunctive effect of n-3 PUFA on bone metabolism in participants with depression is still unknown. This is a pilot study to investigate the dynamics of bone metabolism in depression and evaluate the efficacy of fish oil on bone loss in depression.

Methods: In this study, we focused on the change of bone turnover markers in depression, the effect of n-3 PUFA supplementation on bone turnover markers, and its association with clinical characteristics. A case-control study and a secondary analysis of a previously published randomized clinical trial (NCT03295708) that evaluates the efficacy of n-3 PUFA supplementation in venlafaxine-treated depressed participants have been included.

Results: The levels of PINP (z = -2.233, p = 0.026) in depressed participants were significantly increased compared with healthy controls at baseline. The secondary analysis has shown significant differences exited on CTX (χ 2 = 4.848, p = 0.028) and OSTEOC (χ 2 = 6.178, p = 0.013) between n-3 PUFA and placebo group. The levels of CTX and OSTEOC (p < 0.05) significantly decreased in the placebo group, which indicates that venlafaxine treatment reduces both bone formation and resorption markers. While the levels of OSTEOC and PINP were increased in the n-3 PUFA group (p < 0.05). Moreover, the change in bone turnover markers showed consistency with clinical symptomatic outcomes.

Conclusion: Participants with first-diagnosed, drug-naïve depression show active bone formation. Venlafaxine decreases bone remodeling, while n-3 PUFA increases bone formation, bringing light to preventing and treating bone loss in depression.

Clinical trial registration: ClinicalTrials.gov, NCT03295708.

Keywords: bone formation; bone loss; bone resorption; major depressive disorder; n-3 PUFA.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Flowchart of study trial assessments for participants.
Figure 2
Figure 2
Changes of bone turnover markers between placebo and n-3 PUFA groups *: significantly different after n-3 PUFA supplementation.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Michelson D, Stratakis C, Hill L, Reynolds J, Galliven E, Chrousos G, et al. . Bone mineral density in women with depression. N Engl J Med. (1996) 335:1176–81. doi: 10.1056/NEJM199610173351602, PMID: - DOI - PubMed
    1. Li C, Palka JM, Abdullah N, Adler-Neal A, Banner B, Efseroff B, et al. . Link between depression and bone mineral density in Cooper Center longitudinal study: indirect effects of vitamin D, inflammation, and physical activity. J Affect Disord. (2024) 344:277–83. doi: 10.1016/j.jad.2023.10.062, PMID: - DOI - PubMed
    1. Spangler L, Scholes D, Brunner RL, Robbins J, Reed SD, Newton KM, et al. . Depressive symptoms, bone loss, and fractures in postmenopausal women. J Gen Intern Med. (2008) 23:567–74. doi: 10.1007/s11606-008-0525-0, PMID: - DOI - PMC - PubMed
    1. Yazici KM, Akinci A, Sütçü A, Ozçakar L. Bone mineral density in premenopausal women with major depressive disorder. Psychiatry Res. (2003) 117:271–5. doi: 10.1016/S0165-1781(03)00017-9, PMID: - DOI - PubMed
    1. Chen K, Wang T, Tong X, Song Y, Hong J, Sun Y, et al. . Osteoporosis is associated with depression among older adults: a nationwide population-based study in the USA from 2005 to 2020. Public Health. (2024) 226:27–31. doi: 10.1016/j.puhe.2023.10.022, PMID: - DOI - PubMed

Associated data

LinkOut - more resources